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RESEARCH
Association between the reproductive health of young women 
and cardiovascular disease in later life: umbrella review
Kelvin Okoth,1 Joht Singh Chandan,1 Tom Marshall,1 Shakila Thangaratinam,1,2 G Neil Thomas,1 
Krishnarajah Nirantharakumar,1,3,4 Nicola J Adderley1
AbstrAct
Objective
To consolidate evidence from systematic reviews and 
meta-analyses investigating the association between 
reproductive factors in women of reproductive age and 




Medline, Embase, and Cochrane databases for 
systematic reviews and meta-analyses from inception 
until 31 August 2019.
review methODs
Two independent reviewers undertook screening, data 
extraction, and quality appraisal. The population was 
women of reproductive age. Exposures were fertility 
related factors and adverse pregnancy outcomes. 
Outcome was cardiovascular diseases in women, 
including ischaemic heart disease, heart failure, 
peripheral arterial disease, and stroke.
results
32 reviews were included, evaluating multiple risk 
factors over an average follow-up period of 7-10 years. 
All except three reviews were of moderate quality. A 
narrative evidence synthesis with forest plots and 
tabular presentations was performed. Associations 
for composite cardiovascular disease were: twofold 
for pre-eclampsia, stillbirth, and preterm birth; 
1.5-1.9-fold for gestational hypertension, placental 
abruption, gestational diabetes, and premature 
ovarian insufficiency; and less than 1.5-fold for early 
menarche, polycystic ovary syndrome, ever parity, and 
early menopause. A longer length of breastfeeding 
was associated with a reduced risk of cardiovascular 
disease. The associations for ischaemic heart disease 
were twofold or greater for pre-eclampsia, recurrent 
pre-eclampsia, gestational diabetes, and preterm 
birth; 1.5-1.9-fold for current use of combined oral 
contraceptives (oestrogen and progesterone), recurrent 
miscarriage, premature ovarian insufficiency, and early 
menopause; and less than 1.5-fold for miscarriage, 
polycystic ovary syndrome, and menopausal 
symptoms. For stroke outcomes, the associations 
were twofold or more for current use of any oral 
contraceptive (combined oral contraceptives or 
progesterone only pill), pre-eclampsia, and recurrent 
pre-eclampsia; 1.5-1.9-fold for current use of combined 
oral contraceptives, gestational diabetes, and preterm 
birth; and less than 1.5-fold for polycystic ovary 
syndrome. The association for heart failure was fourfold 
for pre-eclampsia. No association was found between 
cardiovascular disease outcomes and current use of 
progesterone only contraceptives, use of non-oral 
hormonal contraceptive agents, or fertility treatment.
cOnclusiOns
From menarche to menopause, reproductive factors 
were associated with cardiovascular disease in 
women. In this review, presenting absolute numbers 
on the scale of the problem was not feasible; 
however, if these associations are causal, they could 
account for a large proportion of unexplained risk of 
cardiovascular disease in women, and the risk might 
be modifiable. Identifying reproductive risk factors 
at an early stage in the life of women might facilitate 
the initiation of strategies to modify potential 
risks. Policy makers should consider incorporating 
reproductive risk factors as part of the assessment of 




Globally, one third, or 17.9 million, of total annual 
deaths are attributable to cardiovascular disease.1 The 
incidence of cardiovascular disease has declined since 
the middle of the last century, but less so in women 
than in men. In developed countries,2-4 the incidence 
of cardiovascular disease has declined in older age 
groups (≥55), but has stagnated or increased in adults 
aged less than 55.3 5 For instance, in the United 
States, the proportion of hospital admissions for acute 
myocardial infarction for adults aged less than 55 rose 
from 27% between 1995 and 1999 to 32% between 
2010 and 2014.6 The greatest increases were recorded 
in women aged 35-54.6 In Western Australia, between 
1996 and 2007, in adults aged 35-54, hospital 
admissions for acute myocardial infarctions increased 
by 4% in women but decreased by 0.2% in men.4 
Other temporal trend analyses have recorded similar 
increases in women aged 30-54.6-9
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WhAt Is AlreAdy knoWn on thIs topIc
Risk factors specific to women are associated with cardiovascular disease
Individual reviews assessing the implications of these risk factors for 
cardiovascular disease have been published
Clarity on the quality of the evidence is lacking and on how the findings can be 
translated into public health and clinical practice
WhAt thIs study Adds
This study provides a comprehensive list of factors related to reproduction and 
adverse pregnancy outcomes and their association with cardiovascular disease
The review provides clarity on the quality of the evidence, identifies gaps 
in evidence and practice, and provides recommendations that could be 
incorporated into guidelines
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Although many commonalities exist, several diffe-
rences between men and women in terms of risk 
factors for cardiovascular disease are apparent. 
Traditional risk factors for cardiovascular disease, 
such as smoking and diabetes, affect women more than 
men.10 11 Beyond these traditional risk factors, risk 
factors specific to women, such as adverse pregnancy 
outcomes and fertility complications, are under 
recognised.12 Women experiencing adverse pregnancy 
outcomes and issues related to fertility have been 
shown to often have early manifestations of vascular 
changes. Endothelial dysfunction has been shown to 
be prevalent in women with a history of pre-eclampsia 
and recurrent pregnancy loss, and could remain beyond 
pregnancy complications, predisposing these women 
to further vascular complications and serving as a 
prognostic marker for future cardiovascular disease.13 
Biochemical risk factors for cardiovascular disease, 
including raised concentrations of cholesterol, glucose, 
and triglycerides, have been shown to persist many 
years after a hypertensive disorder of pregnancy.14 A 
better understanding of associations with these risk 
factors could be explored in future research to identify 
areas of modifiable risk in women to reduce their long 
term risk of cardiovascular disease.
In developed countries, up to a third of parous 
women experience one or more adverse pregnancy 
outcomes,15 including hypertensive disorders of 
pregnancy, gestational diabetes mellitus, placental 
abruption, and low birth weight and preterm 
births.16 Reproductive risk factors are not limited to 
the obstetric period. Globally, up to 10% of women 
are diagnosed with secondary infertility.17 Common 
causes of secondary infertility, including polycystic 
ovary syndrome, premature ovarian insufficiency, 
endometriosis, and pelvic inflammatory disease, have 
been linked to an increased risk of cardiovascular 
disease.18-20 Also, early age at menarche, early meno-
pause, and use of hormonal contraceptive agents are 
associated with risk of cardiovascular disease.21
In the past three decades, the prevalence of adverse 
pregnancy outcomes has increased in some developed 
countries.22-25 On average, young women could develop 
cardiovascular disease events as early as a decade 
after experiencing an adverse pregnancy outcome.26 27 
Young women who develop acute coronary syndromes 
have longer stays in hospital after admission, higher 
readmission rates, and higher mortality than men.7 28 
Moreover, women with pre-eclampsia have six times 
the risk of readmission for acute coronary syndromes 
at one year and tend to present with a more serious 
type of myocardial infarction than women without 
pre-eclampsia.29 Prediction models for traditional 
risk factors for cardiovascular disease are less optimal 
in young adults.30 31 Also, only 49% of primary care 
physicians in the US said they were confident in the 
assessment of the risk of cardiovascular disease in 
women.32
Adverse pregnancy outcomes and cardiovascular 
disease share common (traditional) risk factors, 
including hypertension, hyperglycaemia, and obesity. 
In a Norwegian cohort study, blood pressure and body 
mass index were linked to 77% of the excess risk of 
cardiovascular disease in women with hypertensive 
disorders of pregnancy.33 Up to 15% of the risk of 
coronary heart disease in young women (aged <65) 
could not be accounted for by traditional risk factors.34
Several systematic reviews have looked at risk 
factors specific to women and cardiovascular disease 
but they evaluated different risk factors and different 
outcomes. An umbrella review is a review of existing 
systematic reviews and meta-analyses.35
The aim of the study was to conduct an umbrella 
review of systematic reviews evaluating the association 
between risk factors specific to women (adverse 
pregnancy outcomes and issues related to fertility) and 
cardiovascular disease outcomes. This umbrella review 
will provide decision makers with a consolidated 
source of high quality studies on this subject. This 
review will help in developing care pathways which 
consider a broader range of factors specific to women 
than are currently considered, in particular those risk 
factors that have the potential to be modified to reduce 
the risk of cardiovascular disease in women at high 
risk (such as those with pre-eclampsia, gestational 
diabetes, and polycystic ovary syndrome).36-38 The 
results of this review are presented by the exposure 
of interest (over the life course of women) and by 
cardiovascular outcome.
Methods
An umbrella review is a narrative compilation of 
evidence for several related clinical questions from 
multiple systematic reviews and meta-analyses into 
one usable document with text, tables, and graphics. 
It aims to examine what is known and not known, and 
then to propose recommendations for practice and 
research.39
Objective, population, exposures, and comparator 
In this review, we explored reproductive factors in 
women and their association with cardiovascular 
disease. The umbrella review followed the guidelines 
for Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA), and the protocol 
was registered in PROSPERO (registration No 
CRD42019120076). The population included women 
of reproductive age. 
Exposures were identified through a scoping search 
and consensus with an expert panel (clinicians and 
epidemiologists). The scoping search included search 
terms for women, cardiovascular disease, and risk 
factors, to identify relevant reproductive risk factors. 
These risk factors were related to fertility and adverse 
pregnancy outcomes. Factors related to fertility 
included: age at menarche; age at first pregnancy; 
age at first birth; early natural menopause; premature 
ovarian insufficiency; polycystic ovary syndrome; 
endometriosis; pelvic inflammatory disease; parity; 
gravidity; breastfeeding; use of hormonal contraceptive 
drugs; and fertility treatment. Adverse pregnancy 
outcomes included: pregnancy loss (miscarriage 
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and stillbirth); hypertensive disorders of pregnancy 
(pre-eclampsia and gestational hypertension); low 
birth weight; small for gestational age; gestational 
diabetes; preterm birth; and placental abruption. The 
comparator group included women of reproductive 
age without the reproductive factor of interest (that is, 
controls or unexposed women).
Outcomes
Outcomes included: ischaemic heart disease; angina; 
myocardial infarction; coronary artery disease; 
cerebrovascular accident, including stroke and tran-
sient ischaemic attack; heart failure; peripheral 
arterial disease; and composite cardiovascular disease 
(ischaemic heart disease, cerebrovascular accident, 
heart failure, and peripheral arterial disease).
study design
Systematic reviews or meta-analyses were included. 
A study qualified as a systematic review or meta-
analysis if, at a minimum: it described the conduct of 
the systematic review in adequate detail; an attempt 
was made to identify all of the relevant primary studies 
in at least one database and a search strategy was 
provided; and it performed a quality appraisal of the 
primary studies included.40
Excluded were guidelines, narrative reviews, 
literature reviews, genetic studies, reviews looking 
at atherosclerosis or venous thromboembolism as 
an outcome, and reviews assessing the association 
between hormonal replacement treatment and cardio-
vascular disease.
search strategy
Medline, Embase, and the Cochrane Database of 
Systematic Reviews were searched from inception until 
31 August 2019 without language restrictions. The 
search strategy was developed around the key terms: 
menarche, OR hormonal contraceptives, OR polycystic 
ovary syndrome, OR menopause, OR endometriosis, 
OR hypertensive disorders of pregnancy, OR gesta-
tional diabetes, OR miscarriage, OR stillbirth, OR 
placental abruption, OR low birth weight, OR preterm 
birth, AND cardiovascular disease. The results were 
limited to systematic reviews and meta-analyses with 
a search filter.41 Reference lists of eligible reviews and 
meta-analyses were searched for additional citations. 
Appendix 1 provides a detailed search strategy for 
the Medline database. This strategy was adapted for 
searching Embase and the Cochrane Database of 
Systematic Reviews.
study selection and data extraction
Two reviewers (KO and JSC) independently carried 
out the study selection and data extraction from the 
eligible studies. Data extracted included: author, year 
of publication, number of participants, number and 
type of studies included, appraisal instrument used, 
method of analysis, outcomes assessed, heterogeneity, 
and findings. The study used the data extraction 
form recommended by the Joanna Briggs Institute 
(appendix 2).42
Quality assessment
The online AMSTAR 2 (A MeaSurement Tool to Assess 
systematic Reviews) checklist was used to assess 
methodological quality and assign an overall rating 
for the reviews included.43 Two reviewers (KO and JSC) 
rated the methodological quality of the reviews with 
the AMSTAR 2 quality appraisal instrument.44 In the 
case of disagreements and failed consensus, a decision 
was reached by consulting a third reviewer (NJA).
The AMSTAR 2 quality assessment tool is a 16 
item or domain checklist. Seven of these items are 
considered critical. Shortcomings in any of the critical 
domains could affect the overall validity of a review. 
The domains considered critical are: registration 
of the protocol before starting the review; conduct 
of an adequate search of the literature; providing 
justification for the exclusion of individual studies; 
satisfactory assessment of risk of bias in the studies 
included in the review; use of appropriate statistical 
methods in performing a meta-analysis; accounting 
for risk of bias when interpreting the results; and 
evaluation of the presence and effect of publication 
bias.44
Overlapping and outdated reviews
Associations assessed in two or more reviews over-
lapped if they evaluated the same exposure and 
outcome.45 Incorporating results from reviews with 
overlapping associations could lead to the inclusion 
of primary studies more than once and result in 
biased findings and estimates.46 47 Also, up to 50% 
of published systematic reviews are out of date after 
5.5 years.48 Reviews on cardiovascular disease topics 
have a shorter duration of currency (three years).48 
We categorised overlapping systematic reviews as 
outdated (reviews older than five years or published 
before 2013) and contemporary (reviews published 
after 2013). Overlapping reviews that were out of date 
were excluded at the full text screening stage.
For contemporary reviews found to have overlapping 
associations (that is, investigating the same exposure 
and outcome), a graphical cross tabulation (citation 
matrix) of the overlapping systematic reviews (in 
columns) and the included primary studies (in rows) 
was generated.49 A citation matrix allows the degree 
of overlap to be quantified with a measure known as 
the corrected covered area (CCA).45 CCA, expressed as a 
percentage, is calculated as (N−r)/(rc−r), where N is the 
number of publications included in evidence synthesis 
(or the number of ticked boxes in the citation matrix), r 
is the number of rows, and c is the number of columns. 
Overlap is categorised as very high (CCA >15%), high 
(CCA 11-15%), moderate (CCA 6-10%), or slight (CCA 
0-5%).45 CCA is a validated method of quantifying the 
degree of overlap between two or more reviews, and 
helps the decision process on how to deal with overlap 
when it is present.
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All non-overlapping systematic reviews that met the 
inclusion criteria (Cochrane and non-Cochrane) were 
included in the analysis. Appendix 3 shows the citation 
matrices for all studies with some degree of overlap. 
Overlap between reviews was managed as follows:
•	 Where overlap involved evidence synthesis 
from Cochrane and non-Cochrane reviews, the 
Cochrane review was selected in preference.50 
A recent study examining the effect of different 
inclusion decisions on the comprehensiveness 
and complexity of overviews of reviews for 
healthcare interventions concluded that selecting 
the Cochrane review resulted in the least amount 
of data loss; also, Cochrane reviews were generally 
higher quality and tended to be more recent.51
•	 Where a high degree of overlap (CCA ≥11%) 
between two or more non-Cochrane reviews was 
found, preference was given to the review that (in 
hierarchical order): had the highest rating, and at a 
minimum was rated as moderate quality, assessed 
with the AMSTAR 2 quality assessment tool; was 
most recent; supplied pooled effect estimates 
or had conducted a meta-analysis; and had the 
highest number of studies or participants.50
•	 Where a slight or moderate degree of overlap (CCA 
≤10%) was found, both reviews were retained, 
and the findings compared.
Data synthesis
Systematic reviews and meta-analyses that met the 
inclusion criteria formed the unit of analysis. Only data 
available from reviews were presented. Results from 
reviews were synthesised with a narrative synthesis, 
with tabular presentation of findings and forest plots 
for reviews that performed a meta-analysis. Summary 
tables describing review characteristics and findings 
were also presented.
update of eligible reviews
The framework recommended by Garner et al52 was 
used to determine whether an update was necessary. 
An existing review qualified for an update if all of the 
following were met:
•	 The review was widely cited and achieved a 
minimum rating of moderate with the AMSTAR 
2 quality appraisal tool.44 Reviews with low 
citations or a low quality rating were unsuitable 
for an update.
•	 With the key search terms from the search strategy 
of an existing review, a focused or abbreviated 
search of primary studies53 identified newly 
published studies that met the inclusion criteria 
of the review.
•	 The findings from newly published studies would 
change the conclusion or credibility of the review.
Appendix 4 describes the search strategy used to 
identify newly published studies. With findings from 
newly published studies, we evaluated the effect 
of updating existing reviews which met the above 
eligibility criteria.52 As proposed by Chung et al,53 
we relied on statistical methods (for reviews that 
conducted meta-analyses) and the informed opinion of 
subject experts (for reviews that did not perform meta-
analyses).
In determining whether an original meta-analysis 
was out of date, newly published studies were sorted 
by sample size from the largest to the smallest. A 
fixed effect meta-analysis was then conducted by 
sequentially pooling (from the largest to the smallest) 
the effect estimate from newly published studies with 
the overall effect estimate of the original meta-analysis. 
The aim of this process was to identify whether a full 
update of the review was needed. An original meta-
analysis was considered out of date if the addition 
of newly published studies resulted in a change of 
statistical significance or a change in the relative effect 
size by at least 50%.
Based on the opinion of subject experts (TM and ST), 
the reviews that did not perform a meta-analysis were 
classified as definitely out of date, probably out of date, 
possibly out of date, and still valid. A review that was 
ranked definitely out of date or probably out of date 
was considered a high priority for update.
If an update was considered necessary, the original 
methods used in the conduct of the existing review were 
replicated. Appendix 5 summarises the evaluation 
process for considering reviews for update.54
Patient and public involvement
No patients were involved in setting the umbrella review 
question, in conducting the study, or in interpreting 
and writing up the results. The umbrella review was 
unfunded and was used to answer a specific question, 
where patient and public involvement will take 
place later in the work. We plan to engage with local 
policy makers (National Institute for Health and 
Care Excellence, Royal College of Obstetricians and 
Gynaecologists, Clinical commissioning groups) and 
local charities (British Heart Foundation), and to 
disseminate the research through social media (twitter), 
a press release from the Institute of Applied Health 
Research, University of Birmingham, and sharing of 
the research findings at relevant conferences.
results
literature search
The search retrieved 11 345 articles. After removal of 
duplicates, and screening of titles and abstracts, 88 
articles qualified for full text screening. Preliminary 
assessment of outdated overlapping reviews resulted 
in exclusion of 21 reviews. Applying the inclusion-
exclusion criteria identified 39 reviews for the umbrella 
review. Figure 1 summarises the study selection 
process. Appendix 6 provides the list of excluded 
studies, with reason for exclusion, after screening of 
the titles and abstracts.
methodological quality
Thirty two reviews were rated as moderate in quality 
and seven reviews were rated as low in quality 
(appendix 7). All seven low quality reviews did not 
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meet three of the seven domains considered critical: 
they had not stated that the review methods were 
established before conducting the review; they had 
not used a comprehensive search strategy; and they 
had not provided a list of excluded studies and the 
justification for their exclusion.44
Overlapping and non-overlapping associations
Twenty three reviews reported overlapping associa-
tions.55-77 Overlapping associations included: current 
use of combined oral contraceptives and risk of 
myocardial infarction, n=255 56; use of combined oral 
contraceptives and risk of ischaemic stroke, n=355-67; 
use of combined oral contraceptives and risk of 
haemorrhagic stroke, n=256 71; use of progesterone only 
pill and risk of stroke, n=272 73; use of combined oral 
contraceptives in migraine and risk of stroke, n=274 75; 
early menarche and mortality from cardiovascular 
disease, n=276 77; early menopause and risk of fatal 
cardiovascular disease, n=357-59; pre-eclampsia and 
risk of cardiovascular disease, n=260 61; gestational 
diabetes and risk of cardiovascular disease, n=362 63 69; 
preterm birth and risk of cardiovascular disease, 
n=360 64 65; and polycystic ovary syndrome and risk 
of cardiovascular disease, n=3.66 68 70 Appendix 8 
describes the general characteristics of the reviews 
with overlapping associations, including the decision 
to retain or exclude an association from the analysis.
Appendix 3 provides an example of the assessment of 
the degree of overlap with a citation matrix. Appendix 
9 lists the thirty two reviews with non-overlapping 
associations that were included in the analysis and 
the seven contemporary reviews that were excluded 
because of overlap.
study characteristics of reviews with non-
overlapping associations
Factors related to fertility investigated in the included 
reviews were use of hormonal contraceptive agents 
(n=9), fertility treatment (n=1), early menarche 
(n=2), polycystic ovary syndrome (n=3), menopause 
(n=4), parity (n=2), and breastfeeding (n=1). Adverse 
pregnancy outcomes included miscarriage (n=1), pre-
eclampsia (n=2), gestational diabetes (n=2), preterm 
births (n=3), and multiple adverse pregnancy out- 
comes (n=1). One study reviewed risk factors related 
to fertility and adverse pregnancy outcomes but was 
limi ted to heart failure as an outcome (n=1). Of the 32 
re-views included in the analyses, 24 conducted meta-
analyses as the main form of evidence synthesis. The 
median length of follow-up was about 10 years for 
studies on risk factors related to fertility and 7.5 years 
for studies on adverse pregnancy outcomes. Supple-
mentary table 1 summarises the general characteristics 
of the reviews and meta-analyses included in the 
umbrella review.
Records identified through other sources
Full text articles excluded
Outdated reviews with overlapping
  associations
Full text excluded for other reasons
21
28
Records screened aer duplicates removed
Records identified through database searching
Records excluded
Full text articles assessed for eligibility
Total studies that met inclusion criteria
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Fig 1 | Preferred reporting items for systematic reviews and meta-analyses (Prisma) flow diagram
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reproductive factors (related to 
fertility) and fatality type
effect size (95% ci)
composite cardiovascular disease ischaemic heart disease stroke heart failure
early menarche
Non-fatal HR 1.15 (1.02 to 1.28) — — —
Fatal RR 0.99 (0.98 to 1.01) RR 0.97 (0.95 to 0.99) RR 0.98 (0.95 to 1.01) —
Fatal and non-fatal — —  — —
Oral contraceptive pill use
Non-fatal — — Ischaemic subtype,  
OR 2.47 (2.04 to 2.99)
—
Fatal — — — —
Fatal and non-fatal — — Haemorrhagic subtype,  
OR 1.39 (1.05 to 1.83)
—
current combined oral contraceptive use
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal — Myocardial infarction,  
RR 1.6 (1.3 to 1.9)
Ischaemic subtype,  
RR 1.7 (1.5 to 1.9)
—
Progesterone only pill use
Non-fatal — Myocardial infarction,  
RR 0.98 (0.66 to 1.47)
RR 1.02 (0.72 to 1.44) —
Fatal — — — —
Fatal and non-fatal — — — —
combined oral contraceptives in obese women
Non-fatal — Myocardial infarction, OR 0.88 
to 5.1
OR 0.59 to 4.6 —
Fatal — — — —
Fatal and non-fatal — — — —
Oestrogen containing contraceptives in women with migraine
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal — — Ischaemic subtype,  
OR 2.08 to 16.9
—
combined oral contraceptives in women with dyslipidaemia
Non-fatal — Myocardial infarction, OR 25 (6 
to 109)
IRR 1.76 (1.51 to 2.06) —
Fatal — — — —
Fatal and non-fatal — — — —
combined oral contraceptives in women with hypertension
Non-fatal — Myocardial infarction, OR 6 to 68 Ischaemic subtype,  
OR 3.1 to 14.5
—
Fatal — — — —
Fatal and non-fatal — — — —
combined non-oral hormonal contraceptives
Non-fatal — Myocardial infarction, OR 0.2 to 
OR 1.6
OR 0.8 to 1.2 —
Fatal — — — —
Fatal and non-fatal — — — —
Polycystic ovarian syndrome
Non-fatal OR 1.30 (1.09 to 1.56) OR 1.44 (1.13 to 1.84) OR 1.36 (1.09 to 1.7) OR 3.24 (0.53 to 19.94)
Fatal — — — —
Fatal and non-fatal — — — —
Fertility treatment
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal HR 0.91 (0.67 to 1.25) — HR 1.25 (0.96 to 1.63) —
Parity
Non-fatal RR 0.79 (0.60 to 1.06) — — —
Fatal RR 1.14 (1.09 to 1.18) — — —
Fatal and non-fatal — — — —
breastfeeding
Non-fatal HR 0.77 to 0.93 — — —
Fatal — — — —
Fatal and non-fatal — — — —
Premature ovarian insufficiency
Non-fatal — — — —
Fatal RR 1.24 (0.98 to 1.58) RR 1.48 (1.02 to 2.16) RR 1.00 (0.86 to 1.16) —
Fatal and non-fatal HR 1.61 (1.22 to 2.12) HR 1.69 (1.29 to 2.21) HR 1.03 (0.88 to 1.99) —
table 1 | summary findings for each reproductive risk factor and effect sizes for cardiovascular outcomes
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summary findings
Supplementary table 2 provides a summary of the 
studies included in the umbrella review, with the 
main results, a summary of the relevant existing 
guidelines, and recommendations for future research 
and clinical practice. Table 1 shows the effect sizes for 
each reproductive factor and the risk of cardiovascular 
disease.
table 1 | continued
reproductive factors (related to 
fertility) and fatality type
effect size (95% ci)
composite cardiovascular disease ischaemic heart disease stroke heart failure
early menopause (natural and unnatural)
Non-fatal — RR 1.50 (1.28 to 1.76) - HR 1.36 to 1.66
Fatal RR 1.19 (1.08 to 1.31) RR 1.11 (1.03 to 1.20) RR 0.99 (0.92 to 1.07) —
Fatal and non-fatal — — — —
early natural menopause
Non-fatal — — — —
Fatal RR 1.01 (0.91 to 1.13) RR 1.09 (1.00 to 1.18) RR 0.94 (0.86 to 1.03) —
Fatal and non-fatal — — — —
menopausal symptoms
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal RR 1.29 (0.98 to 1.71) RR 1.18 (1.03 to 1.35) RR 1.08 (0.89 to 1.32) —
miscarriage
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal OR 0.83 to 2.69 OR 1.45 (1.18 to 1.78) OR 1.11 (0.72 to 1.69) —
stillbirth
Non-fatal OR 1.49 (1.08 to 2.06) — — —
Fatal OR 2.23 (1.90 to 2.62) — — —
Fatal and non-fatal — — — —
Pre-eclampsia
Non-fatal OR 2.24 (1.72 to 2.93)*;  
OR 2.74 (2.48 to 3.04)†
OR 1.73 (1.46 to 2.06) OR 2.95 (1.10 to 7.90) RR 4.19 (2.09 to 8.38)
Fatal OR 1.73 (1.46 to 2.06) RR 2.10 (1.25 to 3.51) RR 1.97(0.80 to 4.88) —
Fatal and non-fatal — — — —
recurrent pre-eclampsia
Non-fatal — RR 2.40 (2.15 to 2.68) RR 1.69 (1.21 to 2.35) RR 2.88 (2.23 to 3.72)
Fatal — — — —
Fatal and non-fatal — — — —
gestational hypertension
Non-fatal RR 1.67 (1.28 to 2.19) — RR 1.83 (0.79 to 4.22) —
Fatal — — — —
Fatal and non-fatal — — — —
gestational diabetes
Non-fatal — RR 2.09 (1.56 to 2.80) RR 1.25 (1.07 to 1.48) —
Fatal — — — —
Fatal and non-fatal RR 1.98 (1.57 to 2.50) — — —
Placental abruption
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal OR 1.82 (1.42 to 2.33) — — —
Preterm birth
Non-fatal OR 1.63 (1.39 to 1.93) RR 1.49 (1.38 to 1.60) RR 1.65 (1.51 to 1.79) —
Fatal OR 1.93 (1.83 to 2.03) RR 2.11 (1.87 to 2.36) RR 1.30 (0.94 to 1.80) —
Fatal and non-fatal HR 2.01 (1.52 to 2.65) HR 1.38 (1.22 to 1.57) HR 1.71 (1.53 to 1.91) —
recurrent preterm birth
Non-fatal — — — —
Fatal HR 2.1 (1.2 to 3.7) — — —
Fatal and non-fatal HR 1.4 (1.2 to 1.6) HR 1.4 to 1.8 HR 1.8 (1.4 to 2.2) —
low birth weight
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal OR 1.29 (0.91 to 1.83) — — —
small for gestational age
Non-fatal — — — —
Fatal — — — —
Fatal and non-fatal OR 1.09 to 3.50 — — —
OR=odds ratio; HR=hazard ratio; RR=relative risk; IRR=incidence rate ratio.
*Moderate pre-eclampsia.
†Severe pre-eclampsia.
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A life course approach was adopted where exposures 
are presented from menarche to menopause for risk 
factors related to fertility, and from miscarriage to low 
birth weight for adverse pregnancy outcomes.
Factors related to fertility
Early age at menarche
Early age at menarche (<12), compared with menarche 
after the age of 12, was associated with a risk of 
morbidity from composite cardiovascular disease (table 
1).78 No association between early age at menarche and 
mortality from cardiovascular disease was found.76 
When examined by subtype of cardiovascular disease, 
an association between early age at menarche and risk 
of mortality from ischaemic heart disease was seen, 
but no association with mortality from stroke.
Use of hormonal contraceptive agents
Oral contraceptives and non-oral forms of com-
bined hormonal contraceptives were associated 
with an increased risk of arteriothrombotic events 
(table 1).55 67 79
Use of oral contraceptives
Current users of any oral contraceptive (combined 
oral contraceptives containing a combination of 
oestrogen and progesterone, or progesterone only pill) 
had an increased risk of stroke compared with non-
current users.67 71 The increase in risk was greater for 
ischaemic stroke67 than haemorrhagic stroke.71 The 
risk of both ischaemic and haemorrhagic stroke was 
greatest in women on higher doses of oestrogen, who 
had hypertension, were smokers, or were aged over 35 
(supplementary table 3).
Current users of combined oral contraceptives had 
a greater risk of developing myocardial infarction 
and stroke than non-current users of combined oral 
contraceptives.55 The same review55 showed that 
the risk was increased in women on higher doses of 
oestrogen but was not related to the dose, generation, 
or type of progesterone (supplementary table 3). In 
contrast, no association was seen between current use 
of the progesterone only pill and risk of myocardial 
infarction or stroke.72
Use of non-oral contraceptive agents
Comparing users of non-oral combined hormonal 
contraceptive agents with users of combined oral 
contraceptives,79 no association with the development 
of myocardial infarction (the results were not meta-
analysed, but odds ratios from individual primary 
studies ranged from 0.2 to 1.6) or stroke (odds ratio 0.8 
to 1.2) was seen but the review was rated as low quality 
(table 1 and supplementary table 4).
Use of hormonal contraceptive agents in women 
with coexisting medical illnesses
Use of hormonal contraceptive agents was associated 
with an additional risk of cardiovascular disease in 
women who had coexisting medical conditions.74 80 81 
The risk of stroke in women diagnosed with migraine 
was 2-16-fold greater for those taking combined 
hormonal contraceptive agents than those not taking 
combined hormonal contraceptives (table 1).74 
Similarly, in women with dyslipidaemia,80 results 
derived from one primary study reported in the 
systematic review showed that users of combined 
hormonal contraceptive agents were at an increased 
risk of myocardial infarction82 and cerebrovascular 
accident compared with non-users (table 1).83 Use 
of combined oral contraceptives in women with 
hypertension women was associated with a much 
higher risk of myocardial infarction (odds ratio 6 to 
68) and ischaemic stroke (odds ratio 3.1 to 14.5) 
than women with normal blood pressure taking 
non-combined oral contraceptives.84 But use of 
combined hormonal contraceptives in women with 
a high body mass index (>27.3 kg/m2) was not found 
to be a multiplicative or additive risk factor for the 
development of myocardial infarction or stroke (table 
1).81 Reviews assessing the association between the use 
of combined oral contraceptives in women with a high 
body mass index and the risk of myocardial infarction 
or stroke were rated as low quality (appendix 7).
Polycystic ovary syndrome
Women with polycystic ovary syndrome had a 1.3-fold 
greater risk of developing composite cardiovascular 
disease than women who did not have polycystic 
ovary syndrome (table 1).66 This increased risk 
was maintained when examining ischaemic heart 
disease66 and stroke85 separately (supplementary 
table 3). Results from population based studies 
suggested that, compared with healthy controls, 
the risk of cardiovascular events was increased in 
young women in the reproductive age group with 
polycystic ovary syndrome (hazard ratio 1.43, 95% 
confidence interval 1.27 to 1.61); no association was 
seen in postmenopausal women with polycystic ovary 
syndrome (supplementary table 3)70 but this review 
was rated as low quality. Based on the results of one 
cross sectional study,86 no association was found 
between polycystic ovary syndrome and the risk of 
heart failure (table 1 and supplementary table 4).87
Fertility treatment
Women receiving fertility treatment (ovulation 
induction, in vitro fertilisation, and intrauterine 
insemination with drug treatment) had no greater risk 
of developing composite cardiovascular disease or 
stroke than infertile women not on fertility treatment.88
Parity
Mortality from composite cardiovascular disease was 
lower in ever parous women than nulliparous women 
(table 1).89 In a dose-response analysis, the association 
between ever parity and mortality from composite 
cardiovascular disease followed a J shaped curve with 
the risk lowest at a parity of four. For non-fatal events,90 
however, the risk of composite cardiovascular disease 
was increased in ever parous women, with the risk 
increasing by 4% for each live birth.90
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Breastfeeding
Evidence synthesised from four studies suggested that 
breastfeeding was associated with an overall reduction 
in maternal cardiovascular disease.91 Reviewers 
presented only a narrative review, without a meta-
analysis (supplementary table 4). Compared with 
women who did not breastfeed, two US cohort studies 
found that morbidity from myocardial infarction92 
and composite cardiovascular disease93 was lower in 
women with a lifetime length of lactation of more than 
12 months. In a cohort of Chinese women,94 mortality 
from ischaemic heart disease but not stroke was lower 
in women who ever breastfed than in those who never 
breastfed. In a cohort of Norwegian women,95 women 
aged 65 or younger and who never breastfed were at a 
higher risk of mortality from stroke than women who 
ever breastfed.
Menopause
Overall, women who experienced menopause earlier 
than age 40 (premature ovarian insufficiency) had a 
1.6-fold risk of developing composite cardiovascular 
disease compared with women without premature 
ovarian insufficiency.96 This association was related 
to the development of ischaemic heart disease96; no 
association was found with stroke. These findings were 
also reflected in the association with mortality risk 
from ischaemic heart disease, but not mortality from 
stroke or composite cardiovascular disease.59
Women who had experienced early (aged <45) 
menopause (natural and unnatural) had a 20% higher 
risk of mortality after cardiovascular disease than 
women who had experienced menopause at age 45 or 
older.57 Specifically, an increased risk of developing 
ischaemic heart disease (fatal and non-fatal outcomes) 
but not stroke was seen.57
Early (aged <45) natural menopause was not 
associated with a risk of mortality from composite 
cardiovascular disease or stroke, but was associated 
with a risk of mortality as a result of ischaemic 
heart disease.59 No association was seen between 
menopausal symptoms and risk of composite cardio-
vascular disease or stroke compared with women 
without menopausal symptoms97 but the risk was 
increased for ischaemic heart disease.
adverse pregnancy outcomes
Pregnancy loss (miscarriage and stillbirth)
A history of miscarriage was not associated with an 
increased risk of composite cardiovascular disease (table 
1).60 In a review exploring individual cardiovascular 
diseases, miscarriage was linked to a higher risk of 
ischaemic heart disease but not of stroke.98 Women with 
a history of stillbirth had a greater risk of morbidity and 
mortality from composite cardiovascular disease than 
women with no history of stillbirth.60
Hypertensive disorders of pregnancy (pre-eclampsia 
and gestational hypertension)
Overall, women with a history of pre-eclampsia 
(both moderate and severe pre-eclampsia) were at 
an increased risk of mortality and morbidity from 
composite cardiovascular disease compared with 
those without a history of pre-eclampsia (table 1).60 
For subtypes of cardiovascular disease, a history of 
pre-eclampsia was associated with a higher odds of 
experiencing heart failure,61 fatal ischaemic heart 
disease,61 and non-fatal stroke,60 but not fatal stroke.61
A small degree (CCA 5.6%) of overlap was noted 
between two reviews60 61 that investigated the association 
between pre-eclampsia and the risk of morbidity from 
ischaemic heart disease (appendix 3). One review61 
searched for primary studies from 2005 only. The risk 
of non-fatal ischaemic heart disease in women with pre-
eclampsia was 1.7-2-fold in the two reviews.60 61
In comparison with an episode of pre-eclampsia 
followed by a healthy pregnancy, a history of recurrent 
pre-eclampsia was associated with an increased risk 
of composite cardiovascular disease, coronary heart 
disease, heart failure, and cerebrovascular accident.99 
Gestational hypertension was linked to a greater risk of 
morbidity from composite cardiovascular disease but 
not stroke.60
Gestational diabetes mellitus
Women with a history of gestational diabetes had a 
greater risk of composite cardiovascular disease than 
those without gestational diabetes (table 1).62 The risk 
was highest in the first decade after pregnancy.62 When 
the analysis was limited to women who did not go on 
to develop diabetes mellitus after gestational diabetes, 
the risk was slightly less but remained statistically 
significant (supplementary table 3).62 The risk persisted 
when analysed by subtype of cardiovascular disease 
(coronary artery disease and stroke).63 Evidence of an 
association between gestational diabetes and heart 
failure87 was inconclusive however (supplementary 
table 4).100 101
Placental abruption
A history of placental abruption was associated with 
a higher odds of composite cardiovascular disease.60
Preterm births
Preterm delivery was associated with an increased 
risk of fatal and non-fatal composite cardiovascular 
disease.102 60 For subtypes of cardiovascular disease, 
the risk was increased in non-fatal ischaemic heart 
disease, fatal ischaemic heart disease, and non-fatal 
stroke.64 The risk of composite cardiovascular disease 
was greater in women with multiple preterm births 
than in women with one preterm birth (table 1 and 
supplementary table 4).65
Low birth weight and small for gestational age
The risk of composite cardiovascular disease tended 
to be higher in women with babies of low birth weight 
than in women who delivered babies with an average 
birth weight (table 1).60 Small for gestational age was 
linked to an increased risk of morbidity and mortality 
from maternal cardiovascular disease (odds ratio 1.09 
to 3.50) (supplementary table 4).60
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Reviews eligible for update
We considered three reviews for update: assessing 
breastfeeding and the risk of cardiovascular disease,91 
assessing miscarriage and the risk of stroke,98 
and assessing gestational diabetes and the risk of 
stroke.63 Breastfeeding and the risk of cardiovascular 
disease was considered eligible for update because of 
conflicting evidence in the original review; findings for 
breastfeeding and the risk of cardiovascular disease 
risk are presented as a narrative summary in line with 
the method used in the original review. A meta-analysis 
was performed for miscarriage and the risk of stroke, 
and for gestational diabetes and the risk of stroke, 
to detect a signal indicating that the review would 
require a full update (as outlined above; eg, inclusion 
of a large new study that would result in a change to 
the conclusions of an existing review). After the meta-
analysis, a full update was not considered necessary.
Miscarriage
A large (1 031 279 participants) Danish cohort study103 
noted that women who had a miscarriage were at a 
higher risk of stroke (incidence rate ratio 1.16, 95% 
confidence interval 1.07 to 1.25). Incorporating the 
results in the meta-analysis on the risk of stroke with 
those of the existing systematic review98 did not alter the 
significance of the association between miscarriage and 
stroke. Figure 2 shows a forest plot of the results of the 
individual studies and the updated meta-analysis.103-106
Gestational diabetes
Two recent studies107 108 found no association between 
gestational diabetes and the risk of stroke (hazard ratio 
1.10, 95% confidence interval 0.75 to 1.61; incidence 
rate ratio 0.95, 95% confidence interval 0.51 to 1.77, 
respectively). When the results were incorporated into 
the meta-analysis on gestational diabetes and risk of 
stroke,63 the association between gestational diabetes 
and risk of stroke was maintained (risk ratio 1.21, 95% 
confidence interval 1.05 to 1.40). Figure 3 shows a 
forest plot of the results of the individual studies and 
the updated meta-analysis.107-110
Breastfeeding
After the original review,91 six newly published 
observational studies111-116 (five cohort and one case-
control study) examined the association between 
length of lactation and cardiovascular disease (table 
2; supplementary table 5 provides more results for 
the primary studies in the original systematic review). 
The quality of the studies ranged from low to high 
(appendix 10). A longer length of breastfeeding 
was associated with a reduced risk of non-fatal 
composite cardiovascular disease compared with 
never breastfed in all three cohort studies.111 114 116 
Mortality from composite cardiovascular disease 
tended to be lower in women who breastfed for longer 
than in those who never breastfed, as assessed by 
two cohort studies.111 116 Two cohort studies showed 
that a longer length of breastfeeding was associated 
with reduced morbidity from coronary heart disease 
compared with never breastfed.115 116 In the case-
control study, a U shaped association between length 
of breastfeeding and morbidity from coronary heart 
disease was seen, with the lowest risk in women who 
breastfed for 16-26 months over a total lifetime.112 
Longer length of breastfeeding versus never breastfed 
was associated with reduced morbidity from stroke in 
two cohort studies.113 116 In summary, newly published 
observational studies support an inverse association 
between length of lactation and morbidity or mortality 
from cardiovascular disease.
summary of results by cardiovascular outcome
Composite cardiovascular disease
Preterm birth, pre-eclampsia, and stillbirth were 
associated with a twofold increase in the risk of 
composite cardiovascular disease; premature ova-
rian insufficiency, placental abruption, gestational 
hypertension, and gestational diabetes mellitus were 
associated with a 1.5-1.9-fold increase in the risk; 
and polycystic ovary syndrome, early menopause, 
early menarche, and ever parity were associated with a 
less than 1.5-fold increase in risk. Breastfeeding 
for longer was associated with a reduced risk 
of cardiovascular disease. The forest plot (fig 4) 
shows the results for reviews that conducted a meta-
analysis.57 59 60 62 66 76 78 88-90 96 97 102
No association was found between cardiovascular 
disease outcomes and fertility treatment, current use of 
the progesterone only pill, or use of non-oral hormonal 
contraceptive agents.
  Kharazmi 2011
  Kharazmi 2010
  Pell 2003
  Ranthe 2013
Overall: P=0.14; I2=45.5%
0.72 (0.42 to 1.24)
1.10 (0.65 to 1.85)
1.49 (1.09 to 2.03)
1.16 (1.07 to 1.25)











Fig 2 | Forest plot showing studies investigating the association between miscarriage and risk of stroke. note, weights 
are from random effects analysis
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Ischaemic heart disease
A history of maternal delivery of preterm infants, 
gestational diabetes, pre-eclampsia, and recurrent 
pre-eclampsia were associated with a twofold or more 
increase in the risk of ischaemic heart disease; current 
use of combined oral contraceptives (oestrogen and 
progesterone), premature ovarian insufficiency, early 
menopause, and recurrent miscarriage were associated 
with a 1.5-1.9-fold increased risk; and polycystic ovary 
syndrome, menopausal symptoms, and miscarriage 
were associated with a less than 1.5-fold increased risk 
(fig 5).55 57 60 61 63 64 66 72 76 96-99 102
Stroke
Current use of any oral contraceptives (combined 
oral contraceptives and progesterone only pill), 
recurrent pre-eclampsia, and pre-eclampsia were 
associated with a twofold or more increased risk 
of stroke; maternal delivery of preterm infants, 
gestational diabetes, and current use of combined oral 
contraceptives were associated with a 1.5-1.9-fold 
increase in risk; and polycystic ovary syndrome was 
associated with a less than 1.5-fold increase in risk 
(fig 6).55 57 59 60 61 63 64 67 71 72 76 85 88 96-99 102
Heart failure
Pre-eclampsia was associated with a fourfold increase 
in the risk of heart failure (fig 7).61 99
discussion
This detailed umbrella review synthesised existing 
systematic reviews and meta-analyses into one 
user friendly document. The review has updated a 
previous systematic review on the association between 
breastfeeding and maternal cardiovascular outcomes, 
and identified gaps and proposed recommendations 
for research and practice, particularly with respect to 
relevant UK guidelines (National Institute for Health 
and Care Excellence, Royal College of Obstetricians 
and Gynaecologists, and Faculty of Sexual and 
Reproductive Healthcare).
main findings
Evidence from the umbrella review suggests that current 
use of combined oral contraceptives, use of combined 
hormonal contraceptive agents in women with 
dyslipidaemia, use of combined hormonal contraceptive 
agents in women with hypertension, use of oestrogen 
containing pills in women with mig raine, polycystic 
ovary syndrome, premature ovarian insufficiency, early 
menarche, early menopause, menopausal symptoms, 
parity, pre-eclampsia, recur rent pre-eclampsia, preterm 
births, gestational diabetes, gestational hypertension, 
miscarriages, stillbirths, placental abruption, and small 
for gesta tional age are associated with an increased 
risk of cardiovascular disease outcomes. The review 
on length of lactation and the recently published 
studies suggest that breastfeeding for longer reduces 
the risk of cardiovascular disease. Length of lactation 
might be a proxy for general health state but never 
breastfed was associated with vascular characteristics 
(larger arterial lumen and adventitial diameters) 
linked to a higher risk of cardiovascular disease 
independent of sociodemographic characteristics, 
health related behaviour, family history, and body 
mass index.117  118 The evidence was inconclusive on 
the association between use of combined hormonal 
contraceptive agents in women with a high body 
mass index (>27.3) and the risk of cardiovascular 
disease outcomes. No association was found between 
current use of progesterone only contraceptives, use 
of non-oral combined hormonal contraceptive agents, 
or fertility treatment and the risk of cardiovascular 
disease outcomes. Reviews on endometriosis, pelvic 
inflammatory disease, and anaemia during pregnancy 
were absent.
strengths and limitations
The umbrella review has many strengths. A compre-
hensive search strategy was used to identify relevant 
reviews. The methodological quality of the studies 
included in the review was assessed with the AMSTAR 
2 tool. Where eligible, reviews were updated to ensure 
the evidence was current. Evaluation of CCA and 
reporting of the highest quality and most current review 
from reviews with overlapping associations were used 
to eliminate double counting. Methodological rigour in 
the conduct of the review was achieved by following 
PRISMA guidelines.
Several limitations arose. Lack of data, including 
missing metadata (number of participants and 
events), hindered the reporting of some elements of 
  Carr 2006
  Goueslard 2016
  Daly 2018
  Tobias 2017 
Overall: P=0.80; I2=0%
1.27 (0.73 to 2.21)
1.25 (1.07 to 1.48)
0.95 (0.51 to 1.77)
1.10 (0.75 to 1.61)












Fig 3 | Forest plot showing studies investigating the association between gestational diabetes and risk of stroke. note, 
weights are from random effects analysis
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the umbrella review. Certain reproductive factors, 
including endometriosis, pelvic inflammatory disease, 
first trimester bleeding without miscarriage, and 
anaemia in pregnancy, have been linked to an increased 
risk of future cardiovascular disease events.19 20 119-121 
Systematic reviews on these exposures could not be 
identified, however, and therefore these factors were 
not incorporated in our analyses. Conversely, for some 
reproductive factors, including age at first birth,122 
evidence from a systematic review was identified, but 
because of inherent methodological shortcomings,40 
the review did not meet our inclusion criteria.
With the AMSTAR 2 quality appraisal instrument, 
some reviews were rated as low quality, and none of 
the reviews was rated as high in quality. Insufficient 
reporting by review authors rather than shortcomings 
of the review methods could have inadvertently led 
to a downgrading of the quality of the review. Also, 
the reviews included were necessarily based on 
observational evidence; consequently, as noted by 
Grandi et al,60 the possibility of confounding remains 
because of unknown confounders or lack of adjustment 
for known confounders. The review by Grandi et al 
noted that a large number of studies failed to adjust for 
all key risk factors and therefore the results should be 
interpreted with caution. Misclassification of exposure 
or outcome status in the studies included in the review 
is also possible.
methodological issues
The evidence in the umbrella review was from 
observational study designs which are prone to 
study, setting, and objective
study design and par-
ticipants exposure and comparator Outcome
length of breastfeeding  
(effect size (95% ci))
nguyen 2019,111 new south wales, australia
To examine the association between 
breastfeeding and hospital  
admission for cardiovascular  
disease and death
Cohort of 100 864 middle 
aged and parous women
Self-reported breastfeeding, 
never v ever and average  




0-6 months, HR 0.86 (0.78 to 0.96)
6-12 months, HR 0.85 (0.75 to 0.97)
>12 months, HR 0.89 (0.71 to 1.12)
Fatal cardiovascular  
disease
Never breastfed (reference)
0-6 months, HR 0.69 (0.51 to 0.94)
6-12 months, HR 0.59 (0.41 to 0.84)
>12 months, HR 0.67 (0.28 to 1.57)
rajaei 2019,112 stanford, usa
To evaluate the association between 
lactation duration and risk of 
developing non-fatal coronary artery 
disease
Hospital case-control 
study of 643 nulliparous 
and multiparous women 
aged 40-65
Exposure category 1: single 
longest duration of breastfeeding 
of all live births
Non-fatal coronary artery 
disease
Live delivery but never breastfed (reference)
1-4 months, OR 1.57 (0.63 to 3.92)
5-9 months, OR 0.53 (0.2 to 1.39)
10-18 months, OR 0.71 (0.29 to 1.76)
≥19 months, OR 0.89 (0.29 to 2.76)
1-4 months (reference)
5-9 months, OR 0.33 (0.14 to 0.8)
10-18 months, OR 0.47 (0.21 to 1.06)
≥19 months, OR 0.57 (0.2 to 1.65)
Exposure category 2: total  
lifetime length of breastfeeding
Non-fatal coronary artery 
disease
Never breastfed (reference)
0-7 months, OR 1.18 (0.48 to 2.86)
8-15.5 months, OR 0.88 (0.35 to 2.25)
16-26 months, OR 0.59 (0.21 to 1.63)
26.5 months, OR 0.71 (0.26 to 1.93)
0-7 months (reference)
8-15.5 months, OR 0.78 (0.34 to 1.76)
16-26 months, OR 0.45 (0.17 to 1.16)
≥26.5 months, OR 0.62 (0.26 to 1.15)
jacobson 2018,113 usa
To assess the association between 
breastfeeding and risk of stroke and 
whether the association differs by 
ethnicity or race
80 191 parous women 
from the Women’s Health 
Observational Study
Never breastfed (<1 month) v 
ever breastfeeding
Non-fatal stroke Never breastfed (reference)
Ever breastfed, HR 0.77 (0.70 to 0.84)
Length of breastfeeding Never breastfed (reference)
1-6 months, HR 0.81 (0.74 to 0.90)
7-12 months, HR 0.75 (0.66 to 0.85)
≥13 months, HR 0.74 (0.65 to 0.83)
Kirkegaard 2018,114 Denmark
To examine how any, partial, and full 
breastfeeding duration are  
associated with maternal risk of 
hypertension and cardiovascular  
disease and how pre-pregnancy 
body mass index and waist  
circumference influence the  
association
Cohort study of 63 260 
women with liveborn 
singleton infants
Breastfeeding for less than 4 




disease (18 months-15 
years postpartum)
<4 months (reference)
4-10 months, HR 0.68 (0.58 to 0.80)
>10 months, HR 0.61 (0.52 to 0.73)
Breastfeeding for less than 4 
months v breastfeeding for >4 
months (pre-pregnancy  
overweight/obese) 
<4 months (reference)
4-10 months, HR 0.79 (0.64 to 0.98)
>10 months, HR 0.88 (0.71 to 1.10)
Cardiovascular disease risk 
(7-15 years postpartum)
<4 months (reference)
4-10 months, HR 0.77 (0.63 to 0.94)
>10 months, HR 0.77 (0.62 to 0.96)
table 2 | summary of primary observational studies (newly published) investigating the association between breastfeeding and risk of maternal 
cardiovascular disease
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residual confounding. In some instances, evidence 
was derived from one study or pooled studies which 
recorded a small number of events, leading to imprecise 
results. Also, some of the evidence was derived from 
cross sectional studies which are poor in determining 
temporal associations.
Several associations between reproductive factors 
and cardiovascular disease had a high degree of 
between study heterogeneity. Several reviews could 
not evaluate the presence of publication bias because 
of the small number of studies in the meta-analyses.123 
Information from some of the primary studies 
was self-reported, which might lead to potential 
misclassification and recall bias.
relation to evidence based guidelines and other 
reviews
Factors related to fertility
Evidence presented in this review on combined 
hormonal contraceptive agents and combined oral 
contraceptives are in keeping with findings on the 
adverse effects of the use of hormonal contraceptive 
agents reported in current evidence based 
guidelines.124 Also, the findings of this review agree 
with the consensus statement from the European 
Headache Federation, which reported that the risk 
of stroke was greater in women with migraine.125 But 
caution should be exercised in the interpretation of 
findings on the use of combined oral contraceptives 
and the arteriothrombotic risk. Firstly, the between 
study heterogeneity was high. Secondly, publication 
bias was not always assessed so its presence cannot be 
ruled out.55 Finally, results on current use of combined 
oral contraceptives in women with dyslipidaemia and 
current use of combined oral contraceptives in women 
with obesity were imprecise because they included a 
small number of studies. Although the absolute risk 
of cardiovascular disease associated with the use of 
combined oral contraceptives is low (about 10 per 
100 000 person years for myocardial infarction and 
21 per 100 000 person years for stroke),21 a large 
proportion of women (up to 18% in Europe and North 
America in 2019) in the reproductive age group use 
contraceptive pills126; hence clinicians should discuss 
this risk with patients and ensure that women are aware 
of the association between the use of combined oral 
contraceptives and the increased risk of cardiovascular 
disease.
The evidence reported supports the results from an 
overview of reviews that investigated the association 
between polycystic ovary syndrome and system wide 
complications, including cardiovascular disease.68 The 
overview summarised evidence from two systematic 
reviews.66 127 Our review synthesised evidence from 
another three reviews, including one evaluating 
the risk of heart failure,70 85 87 but no evidence of an 
table 2 | continued
study, setting, and objective
study design and par-
ticipants exposure and comparator Outcome
length of breastfeeding  
(effect size (95% ci))
Peters 2017,116 china
To examine the long term effects 
of breastfeeding on cardiovascular 
disease in Asian (Chinese) 
Women
Cohort study of 289 573 
Chinese women aged  
30-79 at baseline
Lifetime lactation duration 




Never breastfed, HR 1.00 (0.95 to 1.06)
0-12 months, HR 0.96 (0.93 to 0.99)
12-24 months, HR 0.97 (0.95 to 0.99)
24-36 months, HR 0.96 (0.94 to 0.98)
36-48 months, HR 0.92 (0.89 to 0.94)
>48 months, HR 0.91 (0.88 to 0.93)
Fatal composite  
cardiovascular disease
Never breastfed, HR 1.00 (0.77 to 1.29)
0-12 months, HR 0.88 (0.74 to 1.04)
12-24 months, HR 0.98 (0.87 to1.09)
24-36 months, HR 0.93 (0.85 to 1.02)
36-48 months, HR 0.81 (0.74 to 0.89)
>48 months, HR 0.86 (0.79 to 0.92)
Non-fatal coronary heart 
disease
Never breastfed, HR 1.00 (0.92 to 1.09)
0-12 months, HR 0.93 (0.89 to 0.99)
12-24 months, HR 0.92 (0.89 to 0.96)
24-36 months, HR 0.86 (0.83 to 0.89)
36-48 months, HR 0.86 (0.82 to 0.90)
>48 months, HR 0.85 (0.82 to 0.89)
Non-fatal stroke Never breastfed, HR 1.00 (0.93 to 1.08)
0-12 months, HR 0.93 (0.89 to 0.97)
12-24 months, HR 0.93 (0.90 to 0.96)
24-36 months, HR 0.91 (0.88 to 0.94)
36-48 months, HR 0.86 (0.82 to 0.89)
>48 months, HR 0.85 (0.82 to 0.89)
Peters 2016,115 european cohort
To assess the association between 




Lifetime duration of  
breastfeeding compared with 
never breastfed 




Never breastfed, HR 1.00 (0.75 to 1.34)
0-3 months HR 0.73 (0.60 to 0.89)
3-6 months HR 0.68 (0.56 to 0.83)
6-12 months HR 0.69 (0.55 to 0.87)
12-23 months HR 0.63 (0.51 to 0.76)
>23 months HR 0.62 (0.45 to 0.86)
OR=odds ratio; HR=hazard ratio.
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increased risk of heart failure in women with polycystic 
ovary syndrome was found. Results on the risk of heart 
failure were based on one cross sectional study that 
reported imprecise results. Moreover, cross sectional 
studies cannot be used to infer causality.
Guidelines on the prevention of cardiovascular 
disease recognise perimenopause and menopause as 
periods when women are vulnerable to cardiovascular 
disease.128 129 In line with findings in the evidence 
based guideline on the management of women with 
premature ovarian insufficiency,130 the evidence we 
evaluated reported an increased risk of ischaemic 
heart disease and cardiovascular disease associated 
with premature menopause. Also, early menopause 
and menopausal symptoms were associated with an 
increased risk of ischaemic heart disease.
Adverse pregnancy outcomes
Findings from our review are consistent with 
European and American evidence based guidelines on 
prevention of cardiovascular disease that highlighted 
pre-eclampsia, gestational diabetes, and preterm 
birth as adverse pregnancy outcomes that potentially 
increase the risk of cardiovascular disease.131-134 
Also, this review reports evidence of an increased risk 
of cardiovascular disease outcomes in women with 
stillbirths, small for gestational age offspring, and 
placental abruption. We reported that the increased 
risk of composite cardiovascular disease but not 
stroke was statistically significant (odds ratio 1.67, 
95% confidence interval 1.28 to 2.19) in women 
with gestational hypertension. These findings are in 
keeping with a meta-analysis,135 published beyond the 
time line of this review, which reported that women 
with gestational hypertension had an increased risk of 
composite cardiovascular disease (relative risk 1.73, 
95% confidence interval 1.43 to 2.09), stroke (1.66, 
0.99 to 2.79), coronary heart disease (1.56, 1.35 to 
1.81), and heart failure (1.70, 1.43 to 2.02).
In an umbrella review,136 an inverse association 
between birth weight and future maternal cardio-
vascular disease was reported (hazard ratio 0.75, 
95% confidence interval 0.67 to 0.84, for every one 
standard deviation increase from the mean weight). An 
analysis reported in another review,60 which excluded 
studies with self-reported low birth weight and those 
that reported less severe forms of cardiovascular 
disease, revealed a statistically significant association 
(odds ratio 1.46, 95% confidence interval 1.11 to 
1.91) between low birth weight and cardiovascular 
disease,60 in agreement with the findings of the 
umbrella review136 (supplementary table 3).
Fertility therapy (Dayan 2017)
Premature ovarian insufficiency (Roeters van Lennep 2016)
Preterm birth (Heida 2016)
Early menarche (Prentice and Vinner 2012)
Parity (Li 2018)
Early menarche (Chen 2018)
Early menopause (Muka 2016)
Premature ovarian insufficiency (Tao 2015)
Gestatational diabetes mellitus (Kramer 2019)
Menopausal symptoms (Muka 2016)
Moderate pre-eclampsia (Grandi 2019)
Severe pre-eclampsia (Grandi 2019)
Polycystic ovary syndrome (Zhao 2016)





Preterm birth (Grandi 2019)
Low birth weight (Grandi 2019)
Placental abruption (Grandi 2019)
Hazard ratio
0.91 (0.67 to 1.25)
1.61 (1.22 to 2.12)
2.01 (1.52 to 2.65)
Relative risk
1.15 (1.02 to 1.28)
1.14 (1.09 to 1.18)
0.99 (0.96 to 1.01)
1.19 (1.08 to 1.31)
1.24 (0.98 to 1.58)
1.98 (1.57 to 2.50)
1.29 (0.98 to 1.71)
Odds ratio
2.42 (1.72 to 2.93)
2.74 (2.48 to 3.04)
1.30 (1.09 to 1.56)
1.63 (1.39 to 1.93)
1.49 (1.08 to 2.06)
2.23 (1.90 to 2.62)
0.79 (0.59 to 1.06)
1.73 (1.46 to 2.06)
1.93 (1.83 to 2.03)
1.29 (0.91 to 1.83)






















































Fig 4 | Forest plot showing results of meta-analyses from reviews that investigated the association between various reproductive factors and risk of 
composite cardiovascular disease. circles indicate non-fatal outcomes, open diamonds fatal outcomes, and filled diamonds combined fatal and non-
fatal outcomes
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biological plausibility
Multifactorial mechanisms might explain the 
increased risk of cardiovascular disease associated 
with various reproductive factors. Families of women 
with a history of reproductive complications were also 
at an increased risk of cardiovascular disease and 
so genetic predispositions could have a role.137 138 
Use of hormonal contraceptive agents might 
result in a homeostasis imbalance by favouring 
procoagulant factors and decreasing anticoagulant 
factors.139 Metabolic derangements linked to the 
risk of cardiovascular disease, including weight 
gain, decreased insulin sensitivity, dyslipidaemia, 
and hypertension, are prevalent in women with risk 
factors for cardiovascular disease specific to women 
(eg, factors related to fertility and adverse pregnancy 
outcomes).140-145 On the other hand, in young women 
aged 50 or younger, prolonged lactation was inversely 
linked to risk factors for cardiovascular disease, 
including total cholesterol, body mass index, waist 
circumference, and hypertension, which might be 
linked to the reduced risk of cardiovascular disease 
noted in these women.146
Endothelial dysfunction, which has been found in 
women with premature menopause and in those with 
adverse pregnancy outcomes, might trigger pregnancy 
complications and remain beyond these complications 
to predispose women to future cardiovascular 
disease.13 147 Parity of four or more is associated with 
an increased risk of cardiovascular disease through an 
accelerated atherosclerotic process in both younger 
and older women.148
implications for practice and public health
The implications for practice include early or 
routine screening and assessment for cardiovascular 
disease and risk factors; routine postpartum follow-
up and monitoring, involving multidisciplinary 
healthcare professionals (eg, general practitioners, 
gynaecologists, cardiologists); improving education 
and awareness for patients and clinicians; and use of 
timely treatment.149 A high proportion of women will 
encounter a clinician for the first time when planning 
for a family and during pregnancy. Obstetricians 
and gynaecologists should, therefore, be involved in 
the referral and follow-up of patients potentially at 
risk. A multidisciplinary approach between general 
practitioners, specialist physicians, and obstetricians 
and gynaecologists is recommended.150 Likewise, 
educating practitioners in the primary care setting 
on the importance of taking a thorough reproductive 
history and recording factors related to fertility or 
adverse pregnancy outcomes is essential. Information 
from this history could prove crucial in identifying 
patients at high risk for prevention of cardiovascular 
disease and follow-up. Our previous study found 
insufficient reporting of gestational diabetes and 
screening for cardiovascular risk factors in these 
Premature ovarian insufficiency (Roeters van Lennep 2016)
Preterm birth (Heida 2016)
Early menopause (Muka 2016)
Gestational diabetes mellitus (Li 2018)
Progesterone only pill (Glisic 2018)
Preterm birth (Wu 2017)
Recurrent pre-eclampsia (Brouwers 2018)
Early menarche (Chen 2018)
Early menopause (Muka 2016)
Premature ovarian insufficiency (Tao 2015)
Pre-eclampsia (Wu 2018)
Preterm birth (Wu 2017)
Combined oral contraceptive (Roach 2016)
Menopausal symptoms (Muka 2016)
Polycystic ovary syndrome (Zhao 2016)
Pre-eclampsia (Grandi 2019)
Miscarriage (Oliver-Williams 2013)
Recurrent miscarriage (Oliver-Williams 2013)
Hazard ratio
1.69 (1.29 to 2.21)
1.38 (1.22 to 1.57)
Relative risk
1.50 (1.28 to 1.76)
2.09 (1.56 to 2.80)
0.98 (0.66 to 1.47)
1.49 (1.38 to 1.60)
2.40 (2.15 to 2.68)
0.97 (0.95 to 0.99)
1.11 (1.03 to 1.20)
1.48 (1.02 to 2.16)
2.10 (1.25 to 2.36) 
2.10 (1.87 to 2.36)
1.60 (1.30 to 1.90)
1.18 (1.03 to 1.35)
Odds ratio
1.44 (1.13 to 1.84)
1.73 (1.46 to 2.06)
1.45 (1.18 to 1.78)
















































Fig 5 | Forest plot showing results of meta-analyses from reviews that investigated the association between various reproductive factors and risk 
of ischaemic heart disease. circles indicate non-fatal outcomes, open diamonds fatal outcomes, and filled diamonds combined fatal and non-fatal 
outcomes
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women.108 Adverse pregnancy outcomes should be 
communicated to primary care and reported in primary 
care records so these factors can be used for future risk 
stratification, and patients recalled for risk assessment 
of cardiovascular disease.
Hospital episodes related to cardiovascular disease 
occurred in 381 458 women in the financial year 
2017-18,151 indicating an incidence of about 113.4 
cardiovascular disease episodes per 10 000 women 
annually. A study focusing only on coronary heart 
disease suggested that 15% of coronary heart disease in 
women younger than 65 cannot be explained by existing 
risk factors.34 Therefore, we believe that if we were to 
look at care pathways of women with reproductive risk 
factors, a large proportion of cardiovascular disease 
would be hypothetically preventable. But quantifying 
how much is preventable is difficult given that many 
of these risk factors might cluster together; also, how 
many of the risk factors are modifiable, and whether, 
if modified, a reduction in cardiovascular events will 
be seen is unclear. Nevertheless, screening for risk 
factors in these women and management of these 
reproductive risk factors might not only reduce the risk 
of cardiovascular disease as a result of the reproductive 
risk factors themselves, but also reduce the risk 
caused by traditional risk factors for cardiovascular 
disease (eg, improving care pathways for women with 
gestational diabetes will enable early identification of 









Fertility therapy (Dayan 2017)
Premature ovarian insufficiency (Roeters van Lennep 2016)
Preterm birth (Heida 2016)
Early menopause (Muka 2016)
Gestational diabetes mellitus (Li 2018)
Progesterone only pill (Glisic 2018)
Preterm birth (Wu 2017)
Recurrent pre-eclampsia (Brouwers 2018)
Early menarche (Chen 2018)
Early menopause (Muka 2016)
Premature ovarian insufficiency (Tao 2015)
Pre-eclampsia (Wu 2018)
Preterm birth (Wu 2017)
Combined oral contraceptive (Roach 2015)
Menopausal symptoms (Muka 2016)
Gestational hypertension (Grandi 2019)
Oral contraceptive pill (Xu 2015)*
Polycystic ovary syndrome (Zhous 2017)
Pre-eclampsia (Grandi 2019)
Oral contraceptive pill (Xu 2018)†
Miscarriage (Oliver-Williams 2013)
Hazard ratio
1.25 (0.63 to 1.63)
1.03 (0.88 to 1.19)
1.71 (1.53 to 1.91)
Relative risk
1.23 (0.98 to 1.53)
1.25 (1.07 to 1.48)
1.02 (0.72 to 1.44)
1.65 (1.51 to 1.79)
1.69 (1.21 to 2.35)
0.98 (0.95 to 1.01)
0.99 (0.92 to 1.07)
1.00 (0.86 to 1.16)
1.97 (0.80 to 4.88)
1.30 (0.94 to 1.80)
1.70 (1.50 to 1.90)
1.08 (0.89 to 1.32)
Odds ratio
1.83 (0.79 to 4.22)
2.47 (2.04 to 2.99)
1.36 (1.09 to 1.70)
2.95 (1.10 to 7.90)
1.39 (1.05 to 1.83)













































Fig 6 | Forest plot showing results of meta-analyses from reviews that investigated the association between various reproductive factors and risk of 












Recurrent pre-eclampsia (Brouwers 2018)
4.19 (2.09 to 8.38)







Fig 7 | Forest plot showing results of meta-analyses from reviews that investigated the association between various 
reproductive factors and risk of heart failure. circles indicate non-fatal outcomes
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implications for future research
Several reproductive factors have been linked to an 
increased risk of ischaemic heart disease, stroke, and 
overall cardiovascular disease. These reproductive 
factors might be linked to the risk of peripheral arterial 
disease and heart failure, and therefore longitudinal 
studies are needed in this area.
Evidence from the review has suggested that women 
with adverse pregnancy outcomes are at risk of future 
cardiovascular disease outcomes. Current guidelines 
on prescription of contraceptives recommend a care-
ful assessment of the eligibility for combined oral 
contraceptives in women with migraine, diabetes, and 
other existing conditions associated with a high risk 
of cardiovascular disease.152 These guidelines do not 
include recommendations on the safety profile of the 
use of combined oral contraceptives in women with 
adverse pregnancy outcomes and other complications 
related to fertility. Also, the interaction between 
adverse pregnancy outcomes, factors related to fer-
tility, and other conditions predominant in women 
(migraine, autoimmune diseases) that predispose to 
cardiovascular disease needs to be investigated.
That pregnancy complications act as a stress test 
that unmasks women who are at an increased risk 
of cardiovascular disease has been postulated.153 
Whether adverse pregnancy outcomes and reproductive 
factors related to fertility directly cause or act as 
stressors that reveal those who are already susceptible 
to cardiovascular disease needs to be determined. This 
information will help in starting preventive strategies 
early. Moreover, the mechanistic pathways between 
these reproductive factors and risk of cardiovascular 
disease need to be determined.154
Prediction models for traditional risk factors for 
cardiovascular disease could underestimate the 
true risk of cardiovascular disease in young women 
because they do not account for risk factors specific 
to women.155 A recent systematic review on risk 
prediction models for cardiovascular disease in 
women noted that only 1.1% of the 260 articles 
included in the review investigated the added value 
of incorporating risk factors specific to women in risk 
prediction models.156 Even in studies that evaluated 
the use of predictors specific to women, however, none 
included predictors such as hypertensive disorders 
of pregnancy, gestational diabetes, polycystic ovary 
syndrome, and premature ovarian insufficiency. 
The benefit of adding reproductive factors to risk 
prediction models for cardiovascular disease needs to 
be extensively evaluated.
Should the reproductive profile prove useful in the 
early prediction of cardiovascular disease, it would 
be equally essential to determine the effectiveness of 
intensive screening and monitoring.157 Conventional 
risk factors for cardiovascular disease, including 
hypertension and body mass index, have been 
associated with an excess risk of cardiovascular 
disease in women with hypertensive disorders of 
pregnancy.33 Determining whether women with 
reproductive profiles that place them at an increased 
risk of cardiovascular disease might be candidates 
for lifestyle changes, including statin treatment, is 
essential. Also, interventions to promote a healthy 
lifestyle, epidemiological data and trends, and 
randomised controlled trials that assess early 
intervention in women with risk factors should be 
evaluated.149
conclusion
In summary, the evidence reported in this umbrella 
review suggests that, from menarche to menopause, the 
reproductive profile of women is associated with their 
future risk of cardiovascular disease. Large prospective 
studies are needed to confirm the association between 
current use of combined oral contraceptives in patients 
with obesity and the risk of cardiovascular disease. 
Similarly, prospective studies with a longer duration 
of follow-up are needed to investigate the association 
between reproductive factors and the risk of heart 
failure. A large proportion of unexplained risk of 
cardiovascular disease in women might be attributable 
to reproductive risk factors but the exact magnitude of 
the effect is unclear. Identification of reproductive risk 
factors at an early stage in the life course of women 
might facilitate the initiation of strategies to modify 
potential risks. Future research on the benefit of adding 
risk factors specific to women to prediction models 
for cardiovascular disease and on the mechanistic 
pathways that underlie the association between 
reproductive factors and cardiovascular disease is 
required. Policy makers should consider incorporating 
reproductive risk factors as part of the risk assessment 
for cardiovascular disease in clinical guidelines.
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